• Explore /
  • Poster
  • / Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).

Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).

Abstract Poster

Authors

null

Vadim S Koshkin

University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Vadim S Koshkin , Nicholas Henderson , Deepak Kilari , Tanya Jindal , Omar Alhalabi , Dory Freeman , Arnab Basu , Pedro C. Barata , Mehmet Asim Bilen , Yousef Zakharia , Hamid Emamekhoo , Sumit Shah , Matthew I. Milowsky , Nancy B. Davis , Shilpa Gupta , Christopher J. Hoimes , Petros Grivas , Joaquim Bellmunt , Matthew T Campbell , Ajjai Shivaram Alva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 514)

DOI

10.1200/JCO.2023.41.6_suppl.514

Abstract #

514

Poster Bd #

K18

Abstract Disclosures

Similar Posters

First Author: Chase Allain Shipp

First Author: Evangelia Vlachou

First Author: Haojie Li

First Author: Haojie Li